CanSino Biologics Begins Trials of Broad Pneumococcal Conjugate Vaccine

MT Newswires Live

05/26

CanSino Biologics (HKG:6185, SHA:688185) initiated a phase 1/2 trial of its 24-valent pneumococcal conjugate vaccine, a broad-spectrum shot designed to prevent infections caused by 24 pneumococcal serotypes, according to a Tuesday filing with the Hong Kong bourse.

The trial will evaluate the vaccine in subjects aged two months and older for the prevention of pneumococcal infections, which can cause diseases such as pneumonia and meningitis.

The new product could expand coverage beyond the company's existing 13-valent pneumococcal vaccine, which was approved in China in June 2025.

The firm said there were currently no 24-valent pneumococcal conjugate vaccines available on the global market.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2638456120"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2638456120\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2638456120?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-26 10:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638456120","market":"us","top_or_hot":-1,"title":"CanSino Biologics Begins Trials of Broad Pneumococcal Conjugate Vaccine","media":"MT Newswires Live","content":"<html><body><p> CanSino Biologics (HKG:6185, SHA:688185) initiated a phase 1/2 trial of its 24-valent pneumococcal conjugate vaccine, a broad-spectrum shot designed to prevent infections caused by 24 pneumococcal serotypes, according to a Tuesday filing with the Hong Kong bourse.</p><p>The trial will evaluate the vaccine in subjects aged two months and older for the prevention of pneumococcal infections, which can cause diseases such as pneumonia and meningitis.</p><p>The new product could expand coverage beyond the company's existing 13-valent pneumococcal vaccine, which was approved in China in June 2025.</p><p>The firm said there were currently no 24-valent pneumococcal conjugate vaccines available on the global market.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CanSino Biologics Begins Trials of Broad Pneumococcal Conjugate Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCanSino Biologics Begins Trials of Broad Pneumococcal Conjugate Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-26 10:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CanSino Biologics (HKG:6185, SHA:688185) initiated a phase 1/2 trial of its 24-valent pneumococcal conjugate vaccine, a broad-spectrum shot designed to prevent infections caused by 24 pneumococcal serotypes, according to a Tuesday filing with the Hong Kong bourse.</p><p>The trial will evaluate the vaccine in subjects aged two months and older for the prevention of pneumococcal infections, which can cause diseases such as pneumonia and meningitis.</p><p>The new product could expand coverage beyond the company's existing 13-valent pneumococcal vaccine, which was approved in China in June 2025.</p><p>The firm said there were currently no 24-valent pneumococcal conjugate vaccines available on the global market.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688185","symbol_name":"康希诺","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2638456120","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2638456120","pubTimestamp":1779761340,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CanSino Biologics  initiated a phase 1/2 trial of its 24-valent pneumococcal conjugate vaccine, a broad-spectrum shot designed to prevent infections caused by 24 pneumococcal serotypes, according to a Tuesday filing with the Hong Kong bourse.The trial will evaluate the vaccine in subjects aged two months and older for the prevention of pneumococcal infections, which can cause diseases such as pneumonia and meningitis.The new product could expand coverage beyond the company's existing 13-valent pneumococcal vaccine, which was approved in China in June 2025.The firm said there were currently no 24-valent pneumococcal conjugate vaccines available on the global market.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688185":"康希诺","06185":"康希诺生物","BK0239":"医药制造","BK1574":"生物医药B类股","BK1515":"抗疫概念","BK1191":"制药","BK1161":"生物科技"},"translate_title":"康希诺生物开始试验广泛的肺炎球菌结合疫苗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688185":0.9,"06185":0.9},"content_text":"CanSino Biologics (HKG:6185, SHA:688185) initiated a phase 1/2 trial of its 24-valent pneumococcal conjugate vaccine, a broad-spectrum shot designed to prevent infections caused by 24 pneumococcal serotypes, according to a Tuesday filing with the Hong Kong bourse.The trial will evaluate the vaccine in subjects aged two months and older for the prevention of pneumococcal infections, which can cause diseases such as pneumonia and meningitis.The new product could expand coverage beyond the company's existing 13-valent pneumococcal vaccine, which was approved in China in June 2025.The firm said there were currently no 24-valent pneumococcal conjugate vaccines available on the global market.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}